Platensimycin: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''Platensimycin''' is a novel [[antibiotic]] that was discovered | {{DISPLAYTITLE:Platensimycin}} | ||
== Overview == | |||
[[File:Platensimycin_skeletal.svg|thumb|right|Skeletal structure of Platensimycin]] | |||
'''Platensimycin''' is a novel [[antibiotic]] compound that was discovered in 2006. It is produced by the bacterium ''[[Streptomyces platensis]]''. Platensimycin is notable for its unique mechanism of action, which involves the inhibition of [[fatty acid synthesis]] in bacteria, a process essential for bacterial cell membrane production. | |||
== Discovery == | == Discovery == | ||
Platensimycin was discovered | Platensimycin was discovered by researchers at [[Merck & Co.]] during a screening of natural products for antibiotic activity. The compound was isolated from a strain of ''Streptomyces platensis'' found in a soil sample. Its discovery was significant because it represented a new class of antibiotics at a time when antibiotic resistance was becoming a major public health concern. | ||
== Mechanism of | == Mechanism of Action == | ||
Platensimycin | Platensimycin functions by inhibiting the enzyme [[FabF]], which is a key component of the [[fatty acid biosynthesis]] pathway in bacteria. By blocking this enzyme, platensimycin effectively halts the production of fatty acids, which are crucial for the formation of bacterial cell membranes. This leads to the death of the bacterial cells. | ||
== | == Spectrum of Activity == | ||
Platensimycin has been shown to be effective against a range of Gram-positive bacteria | Platensimycin has been shown to be effective against a range of [[Gram-positive bacteria]], including [[methicillin-resistant Staphylococcus aureus]] (MRSA) and [[vancomycin-resistant Enterococci]] (VRE). However, it is not effective against [[Gram-negative bacteria]] due to their outer membrane, which prevents the compound from reaching its target. | ||
== Clinical Development == | |||
As of the latest updates, platensimycin is still in the preclinical stages of development. Its potential as a therapeutic agent is being explored, but challenges such as its pharmacokinetic properties and the need for effective delivery methods are areas of ongoing research. | |||
== | == Related Pages == | ||
* [[Antibiotic resistance]] | * [[Antibiotic resistance]] | ||
* [[ | * [[Streptomyces]] | ||
* [[ | * [[Fatty acid synthesis]] | ||
* [[Gram-positive bacteria]] | |||
[[Category:Antibiotics]] | [[Category:Antibiotics]] | ||
[[Category: | [[Category:Streptomyces]] | ||
[[Category: | [[Category:2006 in science]] | ||
Latest revision as of 11:08, 15 February 2025
Overview[edit]
Platensimycin is a novel antibiotic compound that was discovered in 2006. It is produced by the bacterium Streptomyces platensis. Platensimycin is notable for its unique mechanism of action, which involves the inhibition of fatty acid synthesis in bacteria, a process essential for bacterial cell membrane production.
Discovery[edit]
Platensimycin was discovered by researchers at Merck & Co. during a screening of natural products for antibiotic activity. The compound was isolated from a strain of Streptomyces platensis found in a soil sample. Its discovery was significant because it represented a new class of antibiotics at a time when antibiotic resistance was becoming a major public health concern.
Mechanism of Action[edit]
Platensimycin functions by inhibiting the enzyme FabF, which is a key component of the fatty acid biosynthesis pathway in bacteria. By blocking this enzyme, platensimycin effectively halts the production of fatty acids, which are crucial for the formation of bacterial cell membranes. This leads to the death of the bacterial cells.
Spectrum of Activity[edit]
Platensimycin has been shown to be effective against a range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). However, it is not effective against Gram-negative bacteria due to their outer membrane, which prevents the compound from reaching its target.
Clinical Development[edit]
As of the latest updates, platensimycin is still in the preclinical stages of development. Its potential as a therapeutic agent is being explored, but challenges such as its pharmacokinetic properties and the need for effective delivery methods are areas of ongoing research.
